SDZ SER-082

From WikiMD's WELLNESSPEDIA

SDZ SER-082 is a serotonin receptor antagonist that is used in scientific research. It is a selective antagonist for the 5-HT1A receptor, which is a subtype of the serotonin receptor. SDZ SER-082 is used to study the role of 5-HT1A receptors in various physiological processes and diseases, including anxiety, depression, and schizophrenia.

Pharmacology[edit]

SDZ SER-082 acts by binding to 5-HT1A receptors and blocking their activation by serotonin. This inhibits the effects of serotonin, a neurotransmitter that plays a key role in mood regulation, sleep, and other functions. By selectively blocking 5-HT1A receptors, SDZ SER-082 allows researchers to study the specific role of these receptors in the body.

Uses in Research[edit]

SDZ SER-082 is primarily used in preclinical research. It has been used in studies investigating the role of 5-HT1A receptors in anxiety and depression, as well as in the pathophysiology of schizophrenia. In addition, it has been used to study the effects of 5-HT1A receptor antagonism on sleep and circadian rhythms.

Side Effects[edit]

As a research compound, SDZ SER-082 is not intended for human consumption, and its side effects in humans are not well-studied. However, in animal studies, it has been shown to cause side effects such as decreased locomotor activity and increased body temperature.

See Also[edit]

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.